Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $793K rose 17.7% year over year, ahead of the -27.9% change in trailing-twelve-month other income / expenses. Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +17.7% holds above the trailing-twelve-month pace of -27.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.73M USD
- Year-over-year change
- -43.3%
- 4-year CAGR
- +138.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.73M | -43.3% |
| FY2024 | 2024-12-31 | 4.82M | -32.2% |
| FY2023 | 2023-12-31 | 7.11M | +263.4% |
| FY2022 | 2022-12-31 | 1.96M | +2201.2% |
| FY2021 | 2021-12-31 | 85K | — |
Other Income / Expenses vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 other income / expenses of $2.85M is the 9th highest of the 11 companies compared; the peer median is $5.93M.
- Its year-over-year change of -27.9% is the 3rd highest of 11, against a peer median of -44.5%.
- Other income / expenses amounts to 1268.0% of revenue for TNYA, versus a peer median of 33.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $158.99M | +525.4% | +142.9% | 1093.5% | |
| LTM Mar 2026 | $16.3M | -51.1% | -2.8% | 808.4% | |
| LTM Mar 2026 | $10.91M | -38.7% | +40.3% | 29.9% | |
| LTM Mar 2026 | $7.03M | -30.0% | +11.2% | — | |
| LTM Mar 2026 | $6.34M | -47.8% | -14.5% | 37.9% | |
| LTM Mar 2026 | $5.52M | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
| LTM Mar 2026 | $4.79M | +95.0% | +39.6% | — | |
| LTM Mar 2026 | $2.85M | -27.9% | +11.8% | 1268.0% | |
| LTM Mar 2026 | -$1.51M | -146.9% | +2.8% | 2.2% | |
| LTM Mar 2026 | -$2.06M | -113.1% | — | 18.4% | |
| Peer median (excluding TNYA) | $5.93M | -44.5% | +11.2% | 33.9% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.